Effect of ARGX-121 on proteinuria in IgA nephropathy
Part of Immune system & allergy, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests whether a new investigational drug called ARGX-121 can reduce protein in the urine of people with IgA nephropathy (IgAN), a kidney disease. It may help slow the loss of kidney function.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 18 or older
- Diagnosis of IgA nephropathy confirmed by kidney biopsy
- Not pregnant and not currently on dialysis
- No history of cancer or organ transplant
- No active infection or other autoimmune disease
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment called HS-10542 for people with IgA nephropathy, a kidney disease. It aims to see if the drug can safely reduce protein in the urine and help protect kidney function.
This study tests a new ADARx medicine in Chinese adults with specific types of kidney disease (IgAN, C3G, or IC-MPGN). The goal is to see if this treatment can slow kidney damage and help preserve kidney function.
This trial tests an experimental tablet, HSK39297, for people with IgA nephropathy, a kidney disease. It aims to see if the drug is safe and can help reduce protein in the urine, which is a sign of kidney damage.
This trial tests a new medicine called FXS6837 for people with IgA nephropathy, a kidney disease. It aims to see if the drug can help protect kidney function. Participants must have a recent kidney biopsy showing certain features and stable kidney function.
This phase 2a trial tests an experimental drug called RG002C0106 in people with primary IgA nephropathy. The goal is to see if the drug can reduce protein in the urine and protect kidney function.
This study tests an experimental drug called MY008211A for people with IgA nephropathy (a kidney disease). It aims to see if it can safely reduce protein in the urine and protect kidney function.
Hear when a new Immunoglobulin A Nephropathy (IgAN) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.